The global mupirocin calcium cream market is anticipated to grow at a CAGR of nearly 3.2% during the forecast period (2022-2028). Mupirocin calcium cream is used to treat infected cuts or wounds owing to its antibiotic nature that works by stopping the growth of certain bacteria. The major factor expected to drive the market growth is the rising application in the treatment of the symptoms of impetigo, skin infections such as boils, infected hair follicles, furuncle, impetigo, and methicillin-resistant staphylococcus aureus (MRSA) colonization or infection. It is also used before surgery for prevention of preventative intranasal or catheter-site treatment and post-operative wound infection with Staphylococcus aureus. This is effective for reducing the risk of catheter site infection in persons treated with chronic peritoneal dialysis.
Some major players in the market include Glenmark Pharmaceutical Ltd., GlaxoSmithKline plc, and and Teva Pharmaceutical Industries Ltd., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in November 2021, Alembic Pharmaceutical Ltd. announced that the company joint venture Aleor Dermaceuticals (Aleor) has received final approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for Mupirocin Cream USP, 2%. The company added that the approved ANDA is therapeutically equivalent to the Reference Listed Drug product (RLD), Bactroban Cream, 2% of SmithKline Beecham (Cork), and Ireland (SmithKline). The company also stated that Aleor has been granted a competitive generic therapies (CGT) designation for this ANDA and it is eligible for 180 days of CGT exclusivity as it is the first approved applicant.
(Get 15% Discount on Buying this Report)
Get Sample Copy of Global Mupirocin Calcium Cream Market at: https://orionmarketreports.com/request-sample/?id=96488&submit=Request+Sample%0D%0A
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
- By Type
- By Application
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Competitive Landscape- Glenmark Pharmaceutical Ltd., GlaxoSmithKline plc, and and Teva Pharmaceutical Industries Ltd., among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
- Deviation from the pre-COVID-19 forecast
- Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
A full report of Global Mupirocin Calcium Cream Market is available at: https://orionmarketreports.com/global-mupirocin-calcium-cream-market/96488/
Global Mupirocin Calcium Cream Market Report by Segment
By Type
- 15 g/tube
- 30 g/tube
By Application
- Hospitals
- Clinics
- Others
Global Mupirocin Calcium Cream Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Italy
- Spain
- France
- Rest of Europe
Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Rest of the World
- Latin America
- Middle East & Africa
About us:
Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company name: Orion Market Reports
Contact person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
